Curium to become major player in the supply on non carrier added Lu-177
25. Januar 2022 00:00 ET
|
Curium
London, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
15. Dezember 2021 01:05 ET
|
Curium
London and Paris, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Curium welcomes Sakir Mutevelic MD, MSc. As Chief Medical Officer, Sakir leads Curium’s global medical strategy and clinical development for...
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
27. Oktober 2021 02:15 ET
|
Curium
St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
24. August 2021 02:15 ET
|
Curium
ST. LOUIS, MO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Curium announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Cu-64...
Curium Acquires Austrian Radiopharmaceuticals Company IASON
31. Mai 2021 22:00 ET
|
Curium
Paris, May 31, 2021 (GLOBE NEWSWIRE) -- (Graz and Paris – June 1st, 2021) —Curium has successfully completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
05. Mai 2021 10:50 ET
|
Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®
05. Mai 2021 02:30 ET
|
Curium
St. Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network® (NCCN)...
Curium Announces Filing of a Generic Version of DaTscanᵀᴹ (Ioflupane I 123 Injection) in the U.S.
04. Mai 2021 02:30 ET
|
Curium
St. Louis, MO, May 04, 2021 (GLOBE NEWSWIRE) -- Curium announced today that it submitted an abbreviated new drug application for a generic version of DaTscan (Ioflupane I 123 Injection) with the...
Curium to Expand Noblesville Facility’s Workforce
28. April 2021 02:30 ET
|
Curium
St. Louis, MO, April 28, 2021 (GLOBE NEWSWIRE) -- Curium, the world’s largest nuclear medicine company, has announced plans to invest in new jobs at its Noblesville location – furthering its...
RadioMedix & Curium Announce Simplified Coding for DetectnetTM (copper Cu 64 dotatate injection)
23. März 2021 02:15 ET
|
Curium
St. Louis, MO, March 23, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has simplified the...